



NDA 204326/S-002

**SUPPLEMENT APPROVAL**

Neos Therapeutics, Inc.  
Attention: Dorothy Engelking, MS, RAC  
Vice President, Regulatory Affairs  
2940 N. Highway 360, Suite 400  
Grand Prairie, TX 75050

Dear Ms. Engelking:

Please refer to your Supplemental New Drug Application (sNDA) dated and received October 21, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Adzenys XR-ODT (amphetamine extended-release orally disintegrating tablets) 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, and 18.8 mg.

We also refer to our letter dated September 21, 2016, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for all Amphetamine products. This information pertains to the association between the use of amphetamines and serotonin syndrome.

This supplemental new drug application provides for revisions to the labeling for Adzenys XR-ODT is consistent with our September 21, 2016 letter.

**APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**WAIVER OF HIGHLIGHTS SECTION**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the

patient package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact CAPT Kofi Ansah, Pharm.D., Senior Regulatory Project Manager, at (301)796-4158 or email: [Kofi.Ansah@fda.hhs.gov](mailto:Kofi.Ansah@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Mitchell V. Mathis, MD  
Division Director  
Division of Psychiatry  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

MITCHELL V Mathis  
01/04/2017